Illumina Faces Selloff Medicare Backs TruSight Test

Illumina Faces Selloff Medicare Backs TruSight Test

Illumina (NASDAQ: ILMN) experienced several down sessions in early February even as its latest corporate developments reinforced a shift toward clinical genomics and multiomics. Investors digested the finalized fiscal 2025 results, a Medicare reimbursement decision for a key oncology assay, completion of a proteomics acquisition, and China-related export updates — all of which carry direct commercial implications for sequencing consumables and clinical services revenue.

Quarterly and Fiscal Results: steady revenue, healthy cash

Key financials

Illumina’s finalized fiscal 2025 figures largely matched prior guidance. Full-year revenue finished at approximately $4.343 billion. Gross margin remained healthy with GAAP around 66.1% and non-GAAP near 68.2%. The company ended the year with roughly $1.63 billion in cash and equivalents. In Q4 specifically, operating cash flow was about $321 million and free cash flow was $267 million; capital expenditures for the quarter were roughly $54 million.

What the numbers mean

Those results indicate resilient consumables and service demand, particularly as clinical applications now make up a larger share of sequencing consumables revenue. Free cash flow softened versus the prior year’s comparable quarter, but liquidity remained solid to fund ongoing R&D, acquisitions, and commercialization efforts.

Clinical Reimbursement: Medicare backs TruSight Oncology Comprehensive

PLA code and pricing

CMS assigned a proprietary laboratory analysis (PLA) code 0543U and set a Medicare payment of $2,989.55 per TruSight Oncology Comprehensive test, effective January 1, 2026. This formal reimbursement decision provides a stable, standardized coverage path for Medicare patients and the providers treating them.

Commercial impact

Medicare coverage tends to drive broader adoption across hospital systems, regional labs, and oncology clinics because it reduces financial uncertainty for payers and providers. Given Illumina’s disclosure that clinical end users represented a majority share of sequencing consumables in 2025, this reimbursement is a tangible revenue lever rather than speculative policy news.

Strategic moves and product initiatives

SomaLogic acquisition and multiomics push

Illumina completed its acquisition of SomaLogic, strengthening its proteomics capabilities and expanding its multiomics footprint. Management also announced the Billion Cell Atlas, a large-scale data initiative aligned with pharmaceutical partners. Together, these moves signal a deliberate pivot from purely sequencing instruments toward integrated data and clinical products that can generate recurring consumables and analytics revenue.

Leadership and clinical focus

The company appointed a new Chief Medical Officer with deep clinical genomics experience to accelerate clinical adoption and regulatory initiatives — a step that complements the Medicare decision and product portfolio expansion.

Geopolitical and competitive context

China export restrictions eased but approvals remain

China’s Ministry of Commerce lifted an export ban on Illumina sequencers, a positive operational development. However, Illumina remains on China’s “Unreliable Entities List,” meaning instrument sales still require case-by-case approvals. That nuance matters for revenue re‑entry timelines and predictable instrument demand in the region.

Competitive pressure: MGI speed claims

Chinese rival MGI continued to promote ultra‑fast sequencers — including claims of sequencing a human genome in minutes on certain platforms — and introduced mid‑throughput devices that emphasize speed and cost. Those engineering and pricing claims create a competitive dynamic in high‑volume and cost‑sensitive segments, particularly outside U.S. clinical channels where regulatory and reimbursement barriers differ.

Share-price reaction and investor takeaway

In early February trading, Illumina shares fell for multiple consecutive sessions: notable moves included a 2.54% drop to $141.13 and a 4.04% decline to $135.43 on adjacent trading days, with unusually high volume relative to the recent average. The selloff appears driven more by investor sentiment and near‑term positioning than by contradicting fundamentals; the company’s financials, clinical reimbursement outcome, and strategic acquisitions are concrete, measurable developments that support a clearer commercial pathway.

For investors and stakeholders, the near-term focus should be on three measurable indicators: the cadence of TruSight adoption in clinical labs (and related consumables growth), timing and scale of instrument sales into China under the new export conditions, and how Illumina integrates SomaLogic to drive recurring multiomics revenue. Competitive moves by MGI underscore the need to monitor pricing and throughput dynamics in sequencing instrument procurement.

Conclusion

Last week’s news delivered substantive, non‑speculative events for Illumina: finalized FY2025 results that confirm operational stability, Medicare reimbursement that materially improves the commercial profile of a core oncology assay, and strategic acquisitions and data offerings that broaden long‑term revenue channels. These developments create a more tangible revenue runway while leaving visible execution risks tied to competition and China approvals. Investors should prioritize observable adoption metrics and quarter‑over‑quarter consumables trends when assessing the company’s trajectory.